Global CAR T-Cell Therapy Market Size, Status and Forecast 2019-2025

Report / Search Code: RnM3314994  Publish Date: 12 April, 2019

Price
1-user PDF : $ 3900.0  Site PDF : $ 5850.0  Enterprise PDF : $ 7800.0

Description:
Chimeric antigen receptor T cells (also known as CAR T cells) are T cells that have been genetically engineered to produce an artificial T-cell receptor. Chimeric antigen receptors (CARs, also known as chimeric immunoreceptors, chimeric T cell receptors or artificial T cell receptors) are receptor proteins that have been engineered to give T cells the new ability to target a specific protein. The receptors are chimeric because they combine both antigen-binding and T-cell activating functions into a single receptor. CAR-T cell therapy uses T cells engineered with CARs for cancer therapy. The premise of CAR-T immunotherapy is to modify T cells to recognize cancer cells in order to more effectively target and destroy them. Scientists harvest T cells from people, genetically alter them, then infuse the resulting CAR-T cells into patients to attack their tumors. CAR-T cells can be either derived from T cells in a patient's own blood (autologous) or derived from the T cells of another healthy donor (allogenic). Once isolated from a person, these T cells are genetically engineered to express a specific CAR, which programs them to target an antigen that is present on the surface of tumors. For safety, CAR-T cells are engineered to be specific to an antigen expressed on a tumor that is not expressed on healthy cells.

In 2018, the global CAR T-Cell Therapy market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global CAR T-Cell Therapy status, future forecast, growth opportunity, key market and key players.
The study objectives are to present the CAR T-Cell Therapy development in United States, Europe and China.
The key players covered in this study
Celgene (Juno Therapeutics)
Novartis
Gilead (Kite Pharma)
Pfizer
CARsgen Therapeutics
Autolus Therapeutics
Aurora BioPharma
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Celicis
Allogene Therapeutics
Celyad
Market segment by Type, the product can be split into
Allogeneic
Autologous
Market segment by Application, split into
Hospitals
Cancer Research Centers
Others
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global CAR T-Cell Therapy status, future forecast, growth opportunity, key market and key players.
To present the CAR T-Cell Therapy development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of CAR T-Cell Therapy are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents:
Table of Contents
1 Report Overview
   1.1 Study Scope
   1.2 Key Market Segments
   1.3 Players Covered
1.4 Market Analysis by Type
   1.4.1 Global CAR T-Cell Therapy Market Size Growth Rate by Type (2014-2025)
   1.4.2 Allogeneic
   1.4.3 Autologous
1.5 Market by Application
   1.5.1 Global CAR T-Cell Therapy Market Share by Application (2014-2025)
   1.5.2 Hospitals
   1.5.3 Cancer Research Centers
   1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
   2.1 CAR T-Cell Therapy Market Size
   2.2 CAR T-Cell Therapy Growth Trends by Regions
      2.2.1 CAR T-Cell Therapy Market Size by Regions (2014-2025)
      2.2.2 CAR T-Cell Therapy Market Share by Regions (2014-2019)
   2.3 Industry Trends
      2.3.1 Market Top Trends
      2.3.2 Market Drivers
      2.3.3 Market Opportunities

3 Market Share by Key Players
   3.1 CAR T-Cell Therapy Market Size by Manufacturers
      3.1.1 Global CAR T-Cell Therapy Revenue by Manufacturers (2014-2019)
      3.1.3 Global CAR T-Cell Therapy Market Concentration Ratio (CR5 and HHI)
   3.2 CAR T-Cell Therapy Key Players Head office and Area Served
   3.3 Key Players CAR T-Cell Therapy Product/Service
   3.4 Date of Enter into CAR T-Cell Therapy Market
   3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
   4.1 Global CAR T-Cell Therapy Market Size by Type (2014-2019)

5 United States
   5.2 CAR T-Cell Therapy Key Players in United States
   5.3 United States CAR T-Cell Therapy Market Size by Type
   5.4 United States CAR T-Cell Therapy Market Size by Application

6 Europe
   6.2 CAR T-Cell Therapy Key Players in Europe
   6.3 Europe CAR T-Cell Therapy Market Size by Type
   6.4 Europe CAR T-Cell Therapy Market Size by Application

7 China
   7.2 CAR T-Cell Therapy Key Players in China
   7.3 China CAR T-Cell Therapy Market Size by Type
   7.4 China CAR T-Cell Therapy Market Size by Application

8 Japan
   8.2 CAR T-Cell Therapy Key Players in Japan
   8.3 Japan CAR T-Cell Therapy Market Size by Type
   8.4 Japan CAR T-Cell Therapy Market Size by Application

9 Southeast Asia
   9.2 CAR T-Cell Therapy Key Players in Southeast Asia
   9.3 Southeast Asia CAR T-Cell Therapy Market Size by Type
   9.4 Southeast Asia CAR T-Cell Therapy Market Size by Application

10 India
   10.2 CAR T-Cell Therapy Key Players in India
   10.3 India CAR T-Cell Therapy Market Size by Type
   10.4 India CAR T-Cell Therapy Market Size by Application

11 Central & South America
   11.2 CAR T-Cell Therapy Key Players in Central & South America
   11.3 Central & South America CAR T-Cell Therapy Market Size by Type
   11.4 Central & South America CAR T-Cell Therapy Market Size by Application

12 International Players Profiles
   12.1 Celgene (Juno Therapeutics)
      12.1.1 Celgene (Juno Therapeutics) Company Details
      12.1.2 Company Description and Business Overview
      12.1.3 CAR T-Cell Therapy Introduction
      12.1.4 Celgene (Juno Therapeutics) Revenue in CAR T-Cell Therapy Business (2014-2019)
      12.1.5 Celgene (Juno Therapeutics) Recent Development
   12.2 Novartis
      12.2.1 Novartis Company Details
12.2.2 Company Description and Business Overview
12.2.3 CAR T-Cell Therapy Introduction
12.2.5 Novartis Recent Development

12.3 Gilead (Kite Pharma)
12.3.1 Gilead (Kite Pharma) Company Details
12.3.2 Company Description and Business Overview
12.3.3 CAR T-Cell Therapy Introduction
12.3.4 Gilead (Kite Pharma) Revenue in CAR T-Cell Therapy Business (2014-2019)
12.3.5 Gilead (Kite Pharma) Recent Development

12.4 Pfizer
12.4.1 Pfizer Company Details
12.4.2 Company Description and Business Overview
12.4.3 CAR T-Cell Therapy Introduction
12.4.5 Pfizer Recent Development

12.5 CARsgen Therapeutics
12.5.1 CARsgen Therapeutics Company Details
12.5.2 Company Description and Business Overview
12.5.3 CAR T-Cell Therapy Introduction
12.5.4 CARsgen Therapeutics Revenue in CAR T-Cell Therapy Business (2014-2019)
12.5.5 CARsgen Therapeutics Recent Development

12.6 Alutolus Therapeutics
12.6.1 Alutolus Therapeutics Company Details
12.6.2 Company Description and Business Overview
12.6.3 CAR T-Cell Therapy Introduction
12.6.5 Alutolus Therapeutics Recent Development

12.7 Aurora BioPharma
12.7.1 Aurora BioPharma Company Details
12.7.2 Company Description and Business Overview
12.7.3 CAR T-Cell Therapy Introduction
12.7.5 Aurora BioPharma Recent Development

12.8 Sorrento Therapeutics
12.8.1 Sorrento Therapeutics Company Details
12.8.2 Company Description and Business Overview
12.8.3 CAR T-Cell Therapy Introduction
12.8.5 Sorrento Therapeutics Recent Development

12.9 Mustang Bio
12.9.1 Mustang Bio Company Details
12.9.2 Company Description and Business Overview
12.9.3 CAR T-Cell Therapy Introduction
12.9.5 Mustang Bio Recent Development

12.10 Bluebird Bio
12.10.1 Bluebird Bio Company Details
12.10.2 Company Description and Business Overview
12.10.3 CAR T-Cell Therapy Introduction
12.10.5 Bluebird Bio Recent Development

12.11 Collectis
12.12 Allogene Therapeutics
12.13 Celyad

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources

15.2 Disclaimer